NCT03158064 2026-01-28Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell TumorsMemorial Sloan Kettering Cancer CenterPhase 2 Active not recruiting30 enrolled